Please activate JavaScript!
Please install Adobe Flash Player, click here for download


27 REFERENCES 1 Donath MY: Targeting inflammation in the treatment of type 2 diabetes: time to start. Nature reviews Drug discovery 2014, 13:465–76. 2 Cerasi E: Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 1995, 38:992–7. 3 Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resist­ ance and type 2 diabetes. Nature 2006, 444:840–6. 4 Bonner-Weir S: Islet growth and development in the adult. Journal of molecular endo- crinology 2000, 24:297–302. 5 Kahn BB: Type 2 diabetes: when insulin secretion fails to compensate for insulin re- sistance. Cell 1998, 92:593–6. 6 Robertson RP, Harmon J, Tran PO, Poitout V: Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53 Suppl 1:S119–24. 7 Weir GC, Bonner-Weir S: Five stages of evolving beta-cell dysfunction during pro- gression to diabetes. Diabetes 2004, 53 Suppl 3:S16–21. 8 Prentki M, Nolan CJ: Islet beta cell failure in type 2 diabetes. J Clin Invest 2006, 116:1802–12. 9 Hull RL, Westermark GT, Westermark P, Kahn SE: Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004, 89:3629–43. 10 Harding HP, Ron D: Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 2002, 51 Suppl 3:S455–61. 11 Hotamisligil GS, Erbay E: Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008, 8:923–34. 12 Donath MY, Storling J, Maedler K, Mandrup-Poulsen T: Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. Journal of molecular medicine 2003, 81:455–70. 13 Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY: Pancreatic islet inflamma- tion in type 2 diabetes: from alpha and beta cell compensation to dysfunction.Ar­chives of physiology and biochemistry 2009, 115:240–7.